Trials
Search / Trial NCT06442709

Combined Anti-IL6R and Anticoagulation Therapy in Advanced NPC Patients

Launched by AFFILIATED HOSPITAL OF NANTONG UNIVERSITY · May 28, 2024

Apply for Trial

Trial Information

Current as of March 13, 2025

Active, not recruiting

Keywords

Nasopharyngeal Narcinoma Metastasis Extracellular Vesicles Organ Organ Crosstalk

ClinConnect Summary

Distant metastasis accounts for nasopharyngeal carcinoma (NPC)-related mortalities. Recently, extracellular vesicles (EVs) have been widely explored as key mediators of bidirectional tumor-host cell interactions by mediating pre-metastatic niche (PMN) formation. However, considering the complexity of the human body, multiple organ studies of tumor metastasis remain poorly understood. Here, the investigators have demonstrated the crucial role of the liver-lung axis in the distant metastasis of NPC. The investigators demonstrated mechanistically that hepatocellular derived EVs can be specific...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • • Clinical diagnosis of NPC with distant metastasis
  • • Must be able to swallow tablets
  • Exclusion Criteria:
  • • Liver disease
  • • Blood disease
  • • Long-term use of anticoagulants

Trial Officials

Bo You, Doctor

Principal Investigator

Department of Otorhinolaryngology-Head and Neck Surgery, Affiliated Hospital of Nantong University

About Affiliated Hospital Of Nantong University

The Affiliated Hospital of Nantong University is a leading medical institution dedicated to advancing healthcare through innovative research and clinical excellence. As a prominent sponsor of clinical trials, the hospital is committed to enhancing patient care by conducting rigorous studies that align with ethical standards and regulatory requirements. With a strong emphasis on collaboration among multidisciplinary teams, the hospital leverages its state-of-the-art facilities and expert staff to foster groundbreaking research initiatives aimed at improving treatment outcomes and addressing critical health challenges.

Locations

Nantong, Jiangsu, China

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0